linjc16/ctgov huggingface dataset:
Review of Enteral Formulas in Children

Study Overview
=================
Brief Summary
-----------------
Retrospective review of nutrition enteral formula data documented in medical records.

Detailed Description
-----------------
This is a retrospective review to assess nutrition (calorie and protein) intake of enteral formula data documented in medical records of patients that consumed enteral tube feeding formulas at home.

Official Title
-----------------
Retrospective Review of Enteral Formulas in Medically Complex Children

Conditions
-----------------
Enteral Feeding Intolerance, Tube Feeding, Nutrition Disorder, Child

Intervention / Treatment
-----------------
* Other: Enteral Tube Feeding


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum 12 months enteral feeding History of enteral feeding with intact or semi-elemental formula Exclusion Criteria: Medical records lacking enteral nutrition feeding use

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Enteral formula standard<br>Children fed an intact protein formula | Other: Enteral Tube Feeding<br>* Enteral tube feeding<br>|
| Enteral formula semi-elemental<br>Children fed a semi-elemental protein formula | Other: Enteral Tube Feeding<br>* Enteral tube feeding<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutrition Intake | Assessment of enteral formula calorie and protein intake compared to nutrition prescription | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight | Weight in kilograms | 12 months | 
| Length/height | Length/height (based on age) in centimeters | 12 months | 
| Formula volume consumption | Assessment of enteral formula volume compared to nutrition prescription | 12 months | 
| Stool frequency | Number of stools reported in medical record | 12 months | 
| Ventilator status | Assessment of ventilator change; extubated or continued | 12 months |
Validating a Delirium Prediction Model for Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine the incidence of delirium in adults patients who are admitted at the critical care unit of a Dutch University Hospital with the mapping of relevant delirium risk factors The primary aim is to validate the investigators' developed delirium prediction model for critical care patients. A secondary aim is to find differences between delirious patients and non-delirious patients on different aspects of diagnostics, treatment and care, outcome, length of stay, and inflammation. According to Dutch law, the need to obtain informed consent was waived by the Committee on Research Involving Human Subjects (CMO) of Nijmegen for this observational study (2007/283).

Official Title
-----------------
Validating a Delirium Prediction Model for Critically Ill Patients

Conditions
-----------------
Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all adult patients (18 years and older) admitted at the critical care unit of our hospital Exclusion Criteria: admitted < 12 hours on ICU not able to understand Dutch patients with serious hearing and visibility disabilities mentally retarded patients patients suffering from receptive aphasia delirious before admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| delirious patients<br>minimal any positive CAM-ICU score during ICU admission | |
| non-delirious patients<br>without any positive CAM-ICU score during ICU admission | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| delirium |  | during admission at the critical care | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| markers of inflammation |  | within 24 hours of delirium diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
delirium, critical care, risk factors, prediction, inflammation
Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane Surgery

Study Overview
=================
Brief Summary
-----------------
This study evaluates the safety and efficacy simultaneous, trans-conjunctival, 25-Gauge vitrectomy and phacoemulsification with intraocular lens implant in patients with metamorphopsia and visual impairment due to idiopathic epiretinal membrane and cataract. All 30 patients recruited underwent complete ocular examination, visual acuity measurement with ETDRS, metamorphopsia assessment with M-Charts and Metamorphometry® and foveal thickness evaluation by sd-OCT preoperatively, at 30, 90, 180 days postoperatively.

Official Title
-----------------
Mid-term Clinical Assessment and Correlation Between Metamorphopsia, Visual Acuity and Foveal Thickness in Idiopathic Epiretinal Membrane and Cataract Surgery

Conditions
-----------------
Epiretinal Membrane, Cataract Senile

Intervention / Treatment
-----------------
* Procedure: Phacoemulsification, intraocular lens implant, vitrectomy.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 55 years visual acuity ≤ 20/40 idiopathic epiretinal membrane cataract Amsler test positive for metamorphopsia. Exclusion Criteria: previous ocular interventions other ocular diseases.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Outpatients<br>Phacoemulsification, intraocular lens implant, vitrectomy. | Procedure: Phacoemulsification, intraocular lens implant, vitrectomy.<br>* Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metamorphopsia | Change in spatial degree of distortion perception | Change in metamorphopsia from baseline at 180 days. | 
| Visual Acuity | Change in LogMAR visual acuity | Change in visual acuity from baseline at 180 days | 
| Area of central scotoma | Change in area, in square pixel, of central scotoma | Change in area of central scotoma from baseline at 180 days | 
| Central fovea thickness | Change in fovea thickness in µm at the Sd OCT | Change in fovea thickness from baseline at 180 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metamorphopsia, Epiretinal membrane, Vitrectomy
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Study Overview
=================
Brief Summary
-----------------
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients

Official Title
-----------------
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients

Conditions
-----------------
Pelubiprofen, Celebrex, Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: Pelubiprofen 30 mg
* Drug: Celebrex 200 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males/Females aged 18 80 years Patient who are taking NSAIDs for the treatment of rheumatoid arthritis Patients who belong to ACR functional class 1, 2, 3 Exclusion Criteria: Patients who belong to ACR functional class 4 Patients who are hypersensitive to clinical trial medicines or excipient Patients who have experience of Cerebrovascular bleeding, bleeding disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pelubiprofen 30 mg<br>Pelubiprofen 30 mg, tid | Drug: Pelubiprofen 30 mg<br> <br> |
| Active Comparator: Celebrex 200 mg<br>Celebrex 200 mg, tid | Drug: Celebrex 200 mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in '100 mm pain VAS' value from baseline |  | -14, 0, 14, 28, 42 day |
The Influence of Health Beliefs and Uncertainty on Diabetes Type II Patient Compliance

Study Overview
=================
Brief Summary
-----------------
To determine the predicting factors and indicators of compliance with insulin treatment in Diabetes Type II patients.

Conditions
-----------------
Diabetes Type II

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With complete cognitive abilities Independent functioning Take insulin Exclusion Criteria: Critically ill patients Psychiatric patients

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes Type II Patients<br> | Other: Questionnaire<br>* Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin adherence | Average number of positive responses on the questionnaire scale | Forty minutes |
Vitreous Fragments Length After Pars Plana Vitrectomy

Study Overview
=================
Brief Summary
-----------------
To measure vitreous collagen fragments length after pars plana vitrectomy performed at different cut rates

Detailed Description
-----------------
Pars plana vitrectomy consists in the removal of vitreous obtained with a vitreous cutter. The instruments attracts vitreous in its port through active suction and cuts with a blade at different cut rates. There is no consensus as to which cut rate would be ideal in order to minimize traction, neither there is agreement on whether increasing cut rates generate shorter collagen fragments or the fluid turbulence creates unpredictable flows at the port generating fragments of different length. The investigators plan to gather vitreous cut at 1,000, 2,000, 4,000, 8,000 and 16,000 cuts per minute and measure vitreous collagen average length

Official Title
-----------------
Vitreous Fragments Length After Pars Plana Vitrectomy

Conditions
-----------------
Vitreous Disorder, Vitreous Anomalies

Intervention / Treatment
-----------------
* Procedure: Pars Plana Vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient undergoing pars plana vitrectomy for: macular pucker macular hole- retinal detachment age >18 Exclusion Criteria: unwilling to participate previous trauma vitreous haemorrhage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Pars Plana Vitrectomy|removal of vitreous with vitreous cutter|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| collagen fragment molecular weigth | collagen passed through the vitreous cutter is examined with regard to collagen moecular weigth | at time of surgery |
MR/PET in the Evaluation of Patients With Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy. In MR, new image sequences will be added to the conventional sequences, such as high resolution image, DWI, DCE, cine imaging.

Detailed Description
-----------------
Total 80 patients will be recruited and followed after treatment complete for at least two years. We will compare the staging accuracy of MR/PET and PET/CT, and also analyze parameters that are predictive of disease recurrence and patient survival.

Official Title
-----------------
MR/PET in the Evaluation of Patients With Esophageal Cancer

Conditions
-----------------
Esophageal Cancer

Intervention / Treatment
-----------------
* Device: The imaging biomarkers determined by MR-PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newly diagnosed esophageal cancer patient age older than 20 years Exclusion Criteria: For the safety reason, patients with the following conditions are contraindicated to enter magnetic resonance imaging (MRI) machine due to the high magnetic field, including: cardiac pacemaker, metallic artificial valve, intracranial and mediastinal vascular clips, cardiac defibrillator, nerve stimulator, implanted drug deliver system, metallic foreign body in the eye globe, cochlear implant, metallic fragments in the dangerous body part, Swan-Ganz catheter, and other metallic implants within 8 weeks: such as cardiac valve, stent, coil, filter, and clips. patient who will receive endoscopic local therapy alone unable to finish the standard surgical or radiation treatment history of surgery or radiotherapy to the mediastinum renal insufficiency, contraindication to MR imaging and contrast injection patient who have the severe allergic reaction the Gadollium contrast agent patient who have the claustrophobic symptoms are also not suitable for this MR examination pregnancy or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The imaging biomarkers determined by MR-PET |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MR/PET in the evaluation, patients
Use of Ibuprofen to Prevent IUD Site Effects

Study Overview
=================
Brief Summary
-----------------
This research will determine whether prophylactic use of ibuprofen can prevent common side effects of the copper intrauterine device (IUD) and prevent early removal of the device.

Detailed Description
-----------------
Increased menstrual bleeding and pain are the primary side effects that lead to early removal of the copper intrauterine device (IUD). Ibuprofen and other nonsteroidal anti-inflammatory drugs are a proven treatment for such IUD-induced problems. This study will determine if prophylactic use of ibuprofen can improve continuation rates of the IUD. A total of 2,019 first-time IUD users were recruited in Chile for this double-blind, randomized, placebo-controlled trial. Half of the participants were given ibuprofen and instructions to take 1200 mg daily during menses (for up to 5 days each cycle) for the first six months of IUD use. The other half were asked to take an identical-appearing placebo in the same manner. The primary study endpoint was IUD removal within 12 months of insertion.

Official Title
-----------------
Prophylactic Ibuprofen: Effect on IUD Continuation Rates

Conditions
-----------------
IUD Removal

Intervention / Treatment
-----------------
* Drug: ibuprofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mutually monogamous sexual relationship, less than 6 weeks since last menstrual period, more than six weeks since last pregnancy ended, residency within 50km of clinic, access to telephone, literacy Exclusion Criteria: previous use of an IUD, history of liver and/or kidney disease, current of non-steroidal anti-inflammatory drugs, history of stomach ulcers and/or digestive hemorrhage, previous adverse reaction to ibuprofen and/or aspirin, symptoms of possible vaginal infection, current use of antibiotic or antifungal for genital tract infection, abnormal vaginal discharge, lesions in the vagina, known contraindication to IUD use, more than 3 alcoholic drinks per day

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ibuprofen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IUD removal |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of IUD side effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
randomized controlled trial, prophylactic nonsteroidal antiflammatory drug, IUD removal
Hyperalgesia and NMDA Receptor Antagonist

Study Overview
=================
Brief Summary
-----------------
NMDA receptor is administered and postoperative remote hyperalgesia is investigated.

Detailed Description
-----------------
NMDA receptor is adminstered and postoperative tertiary hyperalgesia is investigated. QST and pain measures for remote hyperalgesia are compared between control and magnesium or ketamine group.

Official Title
-----------------
Hyperalgesia and NMDA Receptor Antagonist

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate
* Drug: ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA1-2 Exclusion Criteria: contraindication to the study drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: magnesium<br>magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries. | Drug: Magnesium Sulfate<br>* magnesium sulfate is added to the patients<br>|
| Experimental: ketamine<br>ketamine is administered to those patients undergoing stated TKA and other operations. | Drug: ketamine<br>* ketamine is added to the patients.<br>|
| Placebo Comparator: control<br>normal saline (placebo) is administered to the patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain | pain (QST and pain measures )until 1 month from the end of the operation | until 1 month from the end of the operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain